home *** CD-ROM | disk | FTP | other *** search
/ Cancer - Principles & Practice of Oncology / Oncology.iso / PPO / CHAP35 / T3_8.GIF < prev    next >
Scale:
Graphics Interchange Format  |  1999-06-07  |  119KB  |  750x470  |  8-bit (240 colors)
Labels: book | bulletin board | earth | plant | poster | sky | vegetarianism
OCR: Series Agent Dose Patients CR PR Endpoint Or Comment PROG ESTOGENS Reifenstein, Jr 252 HPC g/w 314 (30.2% Median survival 20 months Geisler255 MA 40- -80-160 mg/d (14.2 42.8- Bonte et al.254 MPA g/w 106 (53%) Mean survival 10 months Podratz al 150 MPA, HPC 155 (11 .2%) Retrospective 1968 1980 Quinn 955 MPA 400 mg/d 22 (9% Receptor -positive 2/9 responses Thigpen et al.256 MPA 200 mg/d 138 (26%) vs MPA 1000 mg/d 140 18% Lenz er al 15 MA 800 mg/d 50 (26%) Median survival 7.6 months TAMOXIFEN Ouinn Campbeise TAM 40 mg/d 20% Edmondson TAM 20 mg/d (21%) No activity if refractory to progestogens Swenerton TAM 20 mg/d 35 (23%) Rendina et TAM 40 mgid 4P (36% Haid et al 25 TAM 20 mg/d 26 31%) Thigpen 258 TAM 20 mg/d 63 281) No activity with prior therapy TAMOXIFEN PLUS PROGESTOGENS Pandya et al 259 ...